Patent: 9,512,201
✉ Email this page to a colleague
Summary for Patent: 9,512,201
| Title: | Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof |
| Abstract: | The disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to Hepatitis B viruses, and have a broad neutralizing activity against such Hepatitis B viruses. The disclosure further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of Hepatitis B. |
| Inventor(s): | Ingrid Van Den Nieuwenhof, Marijn Van Der Neut Kolfschoten, Constantin Adrian Apetri, Robert H. E. Friesen |
| Assignee: | Janssen Vaccines and Prevention BV |
| Application Number: | US14/428,904 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,512,201
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Adma Biologics, Inc. | NABI-HB | hepatitis b immune globulin (human) | Injection | 103945 | October 23, 2001 | ⤷ Start Trial | 2033-09-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,512,201
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014048910 | ⤷ Start Trial |
| United States of America | 2015232537 | ⤷ Start Trial |
| South Korea | 20150070181 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
